The Half-Life That Won't Quit
IUPAC: (±)-N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine · racemate · MW 309.33 g/mol (freebase) · CAS 54910-89-3 · ATC N06AB03
Fluoxetine (Prozac). The first blockbuster selective serotonin reuptake inhibitor — Eli Lilly LY-110140, approved 1987. A pure competitive SERT reuptake blocker: it sits in the transporter's central substrate site and refuses to move, the same door-blocking logic as cocaine but with >1,000-fold selectivity for the serotonin transporter over its noradrenergic and dopaminergic cousins. Its defining feature is temporal: an active metabolite, norfluoxetine, with a half-life measured in weeks. Trade names: Prozac, Sarafem, Prozac Weekly, Symbyax (with olanzapine), Reconcile (veterinary).
Fluoxetine is a selective, competitive serotonin-reuptake inhibitor. It binds the central orthosteric substrate site (S1) of the serotonin transporter (SERT, gene SLC6A4) — the same pocket that 5-HT itself occupies — and physically blocks reuptake without being translocated. Like cocaine at DAT, it is a non-transported blocker that arrests SERT's alternating-access cycle; unlike cocaine, it is exquisitely selective, with roughly >1,000-fold preference for SERT over NET and negligible dopamine-transporter activity. The immediate consequence is elevated synaptic serotonin. The therapeutic consequence takes weeks and is downstream: receptor adaptation and neuroplasticity, not the acute reuptake block.
Fluoxetine binds the central S1 site (Ki ~1 nM), the pocket lined by Asp98, Tyr176, Phe341 and Ser438. Its trifluoromethyl-phenoxy ring buries in subsite B while the protonated methylamine forms the Asp98 salt bridge — locking SERT outward-open and blocking 5-HT recapture.
SSRIs including fluoxetine also engage a low-affinity allosteric (S2) vestibular site. S2 occupancy slows dissociation of the S1-bound inhibitor, stabilizing the blocked state — a molecular basis for the sustained, near-complete SERT occupancy seen on chronic dosing.
Fluoxetine is a notable 5-HT2C antagonist (Ki ~62 nM) — the strongest such activity among common SSRIs. 5-HT2C blockade disinhibits prefrontal dopamine and norepinephrine release, contributing to its activating, energizing, appetite-suppressing profile.
Off-target NET affinity is weak (Ki ~1,300–1,600 nM), ~1,000× lower than SERT — clinically silent at ordinary doses but a reason very high doses acquire a faint noradrenergic tint. Fluoxetine is functionally SERT-selective across the therapeutic range.
At higher concentrations fluoxetine engages σ1 receptors and blocks several ion channels (Nav, some K+ channels). These contribute little to antidepressant action but are relevant to overdose cardiotoxicity and to the drug's mild membrane-stabilizing effects.
Reuptake block is instant; benefit is not. Weeks of sustained 5-HT elevation desensitize inhibitory 5-HT1A autoreceptors, restoring raphe firing, and drive BDNF/TrkB-mediated hippocampal plasticity — the true substrate of the 2–6 week onset.
The upshot: fluoxetine's pharmacokinetics are slow and its pharmacodynamics are slower still. The receptor is occupied within hours of the first capsule, but the clinical antidepressant effect emerges over weeks as the serotonergic system remodels. This is the mechanistic inverse of a stimulant — no acute reward, no reinforcement, no rush.
Fluoxetine's pharmacokinetics are dominated by two facts: very long half-lives and an active, longer-lived metabolite. Hepatic CYP2D6 (with contributions from CYP2C9, CYP2C19 and CYP3A4) N-demethylates fluoxetine to norfluoxetine, which is essentially equipotent at SERT. The parent drug's half-life is 1–4 days; norfluoxetine's is 7–15 days. Because fluoxetine and norfluoxetine both inhibit CYP2D6, the drug slows its own clearance — elimination is nonlinear and steady state is not reached for 4–6 weeks.
Metabolism cascade: N-demethylation produces the active metabolite; both parent and metabolite are ultimately conjugated and renally cleared. The active step is the first one.
Norfluoxetine (marked ★) is not a detoxification product — it is a fully active SSRI in its own right, roughly equipotent to fluoxetine at SERT, with a half-life two-to-four times longer. The clinically marketed S-norfluoxetine enantiomer (seproxetine) is the more potent form. Together, parent + metabolite give the drug a pharmacological "tail" that persists for 4–6 weeks after the last dose. This is the basis of Prozac Weekly (90 mg once-weekly enteric capsule): the reservoir is so long-lived that weekly dosing maintains meaningful SERT occupancy.
CYP2D6 poor metabolizers (~7–10% of people of European ancestry) accumulate higher fluoxetine exposure but shift the fluoxetine:norfluoxetine ratio; because both are active at SERT, the net pharmacodynamic effect is partly buffered — one of the reasons fluoxetine is comparatively forgiving of metabolic variability.
The single most clinically distinctive feature of fluoxetine is its self-tapering elimination. After stopping, plasma fluoxetine and norfluoxetine decline slowly over weeks — a built-in, gentle auto-taper that no other SSRI provides. The practical result is the lowest incidence of discontinuation (withdrawal) syndrome in the class.
Why short-half-life SSRIs are worse to stop: paroxetine and venlafaxine have half-lives of hours and no long-lived active metabolite. Abrupt cessation drops SERT occupancy quickly, producing the classic discontinuation picture — dizziness, "brain zaps" (paresthesias), nausea, insomnia, irritability, flu-like malaise — within 1–3 days. Fluoxetine's 7–15-day norfluoxetine reservoir blunts that gradient to near zero.
Clinical exploitation: fluoxetine is used deliberately as a "bridge" to discontinue harder-to-stop SSRIs/SNRIs — switch to fluoxetine, then stop it, letting its own slow washout do the tapering. The flip side: because it lingers, the washout before starting an MAOI is 5 weeks, far longer than the standard 2-week SSRI washout (see Harm Reduction).
Beyond its own metabolism, fluoxetine (and norfluoxetine) is a potent inhibitor of CYP2D6 and a moderate inhibitor of CYP2C19 and CYP3A4. This turns fluoxetine into a pharmacokinetic perturber of any co-prescribed CYP2D6 substrate — and because norfluoxetine lingers for weeks, the interaction outlasts the drug itself.
Substrates that accumulate: tricyclic antidepressants, type 1C antiarrhythmics (flecainide, propafenone), many beta-blockers (metoprolol), atomoxetine, risperidone, aripiprazole, and numerous opioids. Plasma levels of these can rise substantially, with downstream toxicity (QT effects, sedation, arrhythmia).
Prodrugs that fail: codeine and tramadol require CYP2D6 to form their active opioid metabolites. Fluoxetine blunts codeine analgesia by blocking its conversion to morphine — while simultaneously adding serotonergic load with tramadol (a dual hazard: reduced analgesia + serotonin-syndrome risk). Tamoxifen's conversion to active endoxifen is likewise impaired.
Time course: because norfluoxetine's half-life is 7–15 days, CYP2D6 inhibition persists for weeks after fluoxetine is stopped — dose adjustments of co-medications must account for the long tail.
Among SSRIs, fluoxetine sits at the activating end of the spectrum — energizing rather than sedating, sometimes to a fault early in treatment. This profile derives from its 5-HT2C antagonism (prefrontal DA/NE disinhibition) and its long, steady exposure. Clinically it carries the broadest label set of the class.
Sustained SERT blockade elevates 5-HT across cortico-limbic circuits; over weeks, 5-HT1A autoreceptor desensitization and hippocampal BDNF/TrkB signaling produce the therapeutic response. FDA-approved for major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, panic disorder, and (as Sarafem) premenstrual dysphoric disorder; with olanzapine (Symbyax) for bipolar depression and treatment-resistant depression.
Blocking 5-HT2C receptors on GABAergic interneurons disinhibits mesocortical dopamine and norepinephrine. Behaviorally this reads as energization, reduced appetite (useful in bulimia), and — early in treatment, before mood lifts — a window of activation, restlessness, and insomnia that must be managed. It is also why fluoxetine is the least weight-gaining and least sedating of the older SSRIs.
Fluoxetine is FDA-approved for major depressive disorder in children aged ≥8 and for OCD in children aged ≥7 — the SSRI with the strongest pediatric evidence base and the guideline first choice in youth depression. This sits alongside a class black-box warning for increased suicidal ideation in children, adolescents, and young adults (<25), mandating close monitoring during initiation and dose changes.
Sexual dysfunction (delayed orgasm, low libido) is common and often persistent; sleep disturbance and early anxiety reflect the activating profile; GI upset and headache are usual on initiation. Hyponatremia (SIADH) and increased bleeding risk (impaired platelet 5-HT uptake, additive with NSAIDs/anticoagulants) are class effects. Fluoxetine mildly prolongs QT — lower risk than citalopram, but relevant in overdose or with other QT drugs.
Fluoxetine is not reinforcing and has no meaningful abuse liability — there is no acute euphoria, no dopamine surge in the accumbens, no compulsive redosing. It is the pharmacological antithesis of the stimulant scaffold profiled elsewhere in this series: same "block the transporter" verb, opposite everything else.
Fluoxetine is conformationally flexible — six rotatable bonds strung along a
phenyl / methylaminopropyl / trifluoromethyl-phenoxy backbone, with no ring fusing the pharmacophore together.
Contrast cocaine's rigid tropane cage (profiled in entry #001): where cocaine arrives pre-organized and loses
almost no entropy on binding, fluoxetine must freeze several torsions to fit the SERT S1 pocket. In FlexAID∆S
terms this is a substantial ΔS_conf penalty — the ligand pays an entropic tax to organize itself,
which its strong enthalpic contacts (the Asp98 salt bridge, the trifluoromethyl-phenoxy burial) must overcome.
The transporter contributes the other half of the ledger. SERT is a conformational machine cycling through
outward-open, occluded and inward-open states; the unbound pocket carries high H_pocket — many
accessible conformers. Fluoxetine binding collapses that distribution, trapping SERT outward-open and
quenching the alternating-access cycle. This entropy collapse of the receptor is the thermodynamic
fingerprint of a high-affinity, non-transported blocker locking a flexible protein into one state.
For a SERT Ki of ~1 nM, the theoretical binding free energy is
ΔG = −RT·ln(Ka) ≈ −12.3 kcal/mol at 298 K — a genuinely tight complex.
The FlexAID∆S reading is that this affinity is enthalpy-driven and entropy-penalized on the ligand
side, entropy-collapsing on the receptor side: a floppy drug and a floppy transporter both surrender
disorder to form one rigid, long-dwelling complex. That long dwell time — reinforced by the allosteric S2 site —
is the molecular echo of the drug's macroscopic signature: it does not let go quickly, at any scale.
Fluoxetine is safe in overdose relative to the tricyclics it replaced, and non-addictive. The real dangers are combination-driven serotonin toxicity, an early activation window, and — paradoxically — its own persistence.
| Target | Affinity | Rel. | Mechanism |
|---|---|---|---|
|
SERT
Serotonin transporter (SLC6A4)
|
Ki ≈ 1 nM
Primary target · 0.3–3.5 nM
|
Reuptake inhibitor | |
|
Norfluoxetine
at SERT · active metabolite
|
Ki ≈ 1–2 nM
Equipotent · T½ 7–15 d
|
Reuptake inhibitor | |
|
5-HT2C
Serotonin 2C receptor (HTR2C)
|
Ki = 62 nM
Activating profile
|
Antagonist | |
|
NET
Norepinephrine transporter (SLC6A2)
|
Ki ≈ 1,300 nM
>1,000× weaker than SERT
|
Weak inhibitor | |
|
DAT
Dopamine transporter (SLC6A3)
|
Ki > 3,000 nM
Negligible
|
Negligible |